AbbVie Beats Revenue Estimates and Raises Guidance, Strengthening Dividend Outlook
AbbVie (NYSE:ABBV) reported Q1 revenue of $15.002 billion, beating estimates by $284 million and raised full-year adjusted EPS guidance to between $14.08 and $14.28. Strong growth in key products like Skyrizi (+30.9%) and Rinvoq (+23.3%), along with a healthy free cash flow (FCF) payout ratio of 65.4%, supports the durability of its dividend.
